Ascrinvacumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ACVRL1/SKR3/TGF-B/TSR-I, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.